Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT) (BOX-DVT)

Bayer

Status: Completed

Conditions: Venous Thrombosis

Treatments: Drug: Rivaroxaban (Xarelto, BAY59-7939)

Study type: Observational

Funder types: Industry

Identifiers

NCT01855100

16852

XA1314BE (Other Identifier)

Details and patient eligibility

About

The objective of this NIS is to assess in a real-life setting, usage patterns and associated outcomes in the management (healthcare resource utilisation and associated costs) of patients with acute deep vein thrombosis treated with Xarelto, in accordance with the terms of the European marketing authorization and the Belgian reimbursement criteria.

Enrollment: 131 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients with a diagnosis of deep vein thrombosis (DVT) within the past 9 months, enabling at least 3 months of therapy

Exclusion criteria

• Patients who do not fulfil the Belgian reimbursement criteria of deep vein thrombosis (DVT)

Trial design

131 participants in 1 patient group

Rivaroxaban

Treatment:

Drug: Rivaroxaban (Xarelto, BAY59-7939)